Sign in

    Donald J. Zurbay

    President and CEO at PATTERSON COMPANIES, INC.
    Board
    Since October 2022
    Age
    57 years
    Tenure
    Started as CFO in June 2018 and was promoted to President and CEO in October 2022.

    Also at PATTERSON COMPANIES, INC.

    KMB
    Kevin M. Barry
    Chief Financial Officer (CFO)
    KMP
    Kevin M. Pohlman
    Chief Operating Officer (COO)
    LBK
    Les B. Korsh
    Chief Legal Officer

    About

    Donald J. Zurbay has been leading PDCO as President and Chief Executive Officer since October 2022 after serving as the Chief Financial Officer from June 2018 to October 2022. His extensive career in finance and leadership includes pivotal roles at St. Jude Medical, Inc. where he served as Vice President and CFO, as well as significant stints at PricewaterhouseCoopers, The Valspar Corporation, and Deloitte & Touche.

    Throughout his professional journey, he has demonstrated strategic financial oversight and leadership acumen, contributing to growth and transformation at every organization he has been part of. In addition to his executive roles, he has also served on the boards of multiple companies including Avedro, Inc., Silk Road Medical, Inc., and Sight Sciences, Inc., which further underscores his broad expertise in both finance and the healthcare sector.

    At 57 years old, he brings a wealth of experience and insight to PDCO, balancing deep industry knowledge with a commitment to innovative leadership. His career reflects a steady progression from financial management roles to executive leadership, making him a central figure in PDCO’s strategic direction.

    $PDCO Performance Under Donald J. Zurbay

    Past Roles

    Organization Role Date Range Details
    Patterson Companies, Inc. (PDCO) Chief Financial Officer (CFO) June 2018 – October 2022 Served as CFO before promotion to President and CEO
    Patterson Companies, Inc. (PDCO) Interim Chief Financial Officer Brief period during transition Served during the transition period before officially becoming CEO
    St. Jude Medical, Inc. Vice President and Chief Financial Officer August 2012 – January 2017 Oversaw accounting, financial, and business development; also held roles as Director of Finance and Corporate Controller
    PricewaterhouseCoopers Assurance & Business Advisory Services Senior Manager 5 years N/A
    The Valspar Corporation General Accounting Manager N/A N/A
    Deloitte & Touche Auditor Started in 1989 N/A
    Avedro, Inc. Director February 2019 – November 2019 Role concluded with the company’s sale

    External Roles

    Organization Role Date Range Details
    Sight Sciences, Inc. Director Since July 2020 Current board seat
    Silk Road Medical, Inc. Director Since March 2018 Current board seat

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Salary$900,001AnnualBase Salary
    All Other Compensation$118,674AnnualBreakdown: Automobile Allowance ($10,596), Executive Life Insurance Premiums ($5,409), Reimbursement for Taxes ($8,194), 401(k) Contributions ($12,641), Travel Benefit ($3,889), Dividends ($77,944)

    Performance Compensation

    Data from  FY 2024

    Annual Cash Incentive Compensation (MICP)

    MetricThresholdTargetMaximumWeight
    Consolidated Adjusted Operating Income$289.4M $340.4M $408.5M 70%
    Consolidated Free Cash Flow$149.1M $175.4M $210.5M 30%
    • Target MICP Award: $1,125,000 (125% of base salary)
    • Actual Payout: $813,713 (72.33% of target)
    • Evaluation Period: Fiscal 2024
    • Conditions: Payout is contingent on achieving the specified financial metrics; if performance falls below the threshold, no payout is made.

    Performance Stock Units (PSUs)

    MetricThresholdTargetMaximum
    3-Year Cumulative EPS90% of target (50% payout)100% (100% payout)115% (160% payout)
    rTSR Modifier0.75x1.00x1.25x
    • PSU Grants (Units): Threshold: 22,550, Target: 60,132, Maximum: 120,264
    • Grant Date: July 1, 2023
    • Grant Date Fair Value: $2,063,129
    • Vesting Schedule: Vesting occurs after a 3-year performance period (fiscal 2024–2026)

    Stock Options

    DetailValue
    Grant DateJuly 1, 2023
    Grant Date Fair Value$1,000,000
    Grant Date Stock Price$33.26 per share
    Vesting ScheduleOne-third annually over 3 years (starting July 1, 2024)
    Expiration DateJuly 1, 2033
    Performance MetricsNone – service-based

    Restricted Stock Units (RSUs)

    DetailValue
    Grant DateJuly 1, 2023
    Grant Date Fair Value$999,995
    Number of RSUs Granted30,066
    Grant Date Stock Price$33.26 per share
    Vesting ScheduleOne-third annually over 3 years (starting July 1, 2024)
    Performance MetricsNone – service-based